Hospital
Cabell Huntington Hospital INC
Cabell Huntington Hospital INC was paid $94.16M by Medicaid between Jan 2018 and Dec 2024, across 614 billing codes. Its largest line is 99285, emergency room visit (most serious) — 8.8% of everything it billed.
33Billing provider infoCABELL HUNTINGTON HOSPITAL INC
HUNTINGTON, WV 25701
HUNTINGTON, WV 25701
33aNPI1073518007assigned 06/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$94.16M
24GClaims2,248,397
24DCodes billed614
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#2 of 26
Median peer was paid$18.33M
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 354,073 | $22.30M | |
| 2019 | 301,066 | $20.01M | |
| 2020 | 396,614 | $17.61M | |
| 2021 | 375,164 | $10.82M | |
| 2022 | 240,453 | $7.28M | |
| 2023 | 324,332 | $8.44M | |
| 2024incomplete | 256,695 | $7.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.8% | 24,854 | 21,218 | $8.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.0% | 35,079 | 30,872 | $4.68M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.9% | 17,027 | 15,685 | $4.60M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.6% | 2,635 | 2,281 | $3.41M |
| J3490 | Unclassified drugs | 3.3% | 57,013 | 21,088 | $3.13M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.2% | 36,971 | 25,146 | $3.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.2% | 38,434 | 34,772 | $2.98M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.5% | 43,576 | 29,200 | $2.35M |
| 80053 | Comprehensive metabolic panel | 2.5% | 135,689 | 102,377 | $2.34M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 8,217 | 7,235 | $2.15M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2.0% | 6,859 | 3,576 | $1.91M |
| G0378 | Hospital observation service, per hour | 2.0% | 6,768 | 5,735 | $1.89M |
602 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 135,975 | $1.79M |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 184,154 | $1.55M |
| J2704 | Injection, propofol, 10 mg | <1% | 26,457 | $915K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,984 | $842K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 5,226 | $808K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19,288 | $802K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,780 | $801K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 27,026 | $799K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,900 | $753K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,162 | $746K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 80,399 | $740K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,247 | $721K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,410 | $714K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,552 | $679K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 8,588 | $668K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 16,361 | $625K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 34,138 | $613K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,350 | $609K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 17,386 | $599K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,549 | $588K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,219 | $586K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,689 | $586K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,127 | $577K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,631 | $575K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,094 | $570K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 6,822 | $552K |
| 96376 | <1% | 9,339 | $548K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 847 | $532K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14,813 | $521K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,208 | $509K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,992 | $505K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17,890 | $488K |
| 81003 | <1% | 46,727 | $474K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,380 | $454K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 718 | $451K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26,880 | $445K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,712 | $445K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,213 | $438K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 8,173 | $390K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,276 | $382K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,847 | $362K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,562 | $358K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,380 | $351K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,498 | $339K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,681 | $321K |
| 82948 | <1% | 23,689 | $318K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 7,548 | $314K |
| 87486 | <1% | 7,375 | $313K | |
| 96415 | <1% | 2,496 | $309K | |
| 64493 | <1% | 1,045 | $296K | |
| 87797 | <1% | 7,374 | $283K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,189 | $274K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,201 | $273K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,583 | $267K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,594 | $266K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 2,013 | $254K |
| 84703 | <1% | 12,175 | $251K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 157 | $242K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,184 | $242K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,249 | $240K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,054 | $236K |
| 20610 | <1% | 4,787 | $234K | |
| 85027 | <1% | 22,281 | $228K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 554 | $225K |
| 84484 | <1% | 15,822 | $223K | |
| 83690 | <1% | 16,588 | $219K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 790 | $212K |
| 80061 | Lipid panel | <1% | 16,564 | $211K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,999 | $205K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,260 | $201K |
| 76830 | Ultrasound, transvaginal | <1% | 2,357 | $200K |
| 64615 | <1% | 2,354 | $199K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,510 | $198K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 582 | $195K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,951 | $194K |
| 95811 | <1% | 357 | $194K | |
| 97161 | <1% | 3,888 | $193K | |
| 87070 | <1% | 10,839 | $191K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,438 | $189K |
| 82805 | <1% | 4,001 | $182K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 4,616 | $182K |
| 73630 | <1% | 6,965 | $180K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,254 | $179K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,615 | $178K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,575 | $178K |
| 88307 | <1% | 1,983 | $177K | |
| 80074 | <1% | 4,262 | $177K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 18,081 | $176K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,489 | $175K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,601 | $175K |
| 73610 | <1% | 6,034 | $173K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 978 | $173K |
| 73564 | <1% | 6,516 | $170K | |
| 71250 | <1% | 2,520 | $168K | |
| 83880 | <1% | 3,546 | $168K | |
| 74018 | <1% | 5,245 | $167K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 851 | $167K |
| 73110 | <1% | 5,078 | $167K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 785 | $163K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,700 | $160K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,744 | $159K |
| 87040 | <1% | 5,500 | $153K | |
| 84439 | <1% | 14,294 | $153K | |
| 73130 | <1% | 5,152 | $150K | |
| 77336 | <1% | 865 | $149K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,248 | $148K |
| 95886 | <1% | 2,928 | $146K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 5,453 | $146K |
| 20553 | <1% | 1,404 | $145K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 588 | $140K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,607 | $138K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 929 | $135K |
| 93971 | <1% | 2,476 | $131K | |
| 47562 | <1% | 39 | $128K | |
| 87507 | <1% | 532 | $128K | |
| 96367 | <1% | 2,720 | $126K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,895 | $125K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,144 | $123K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 909 | $121K |
| 93017 | <1% | 1,875 | $120K | |
| 87186 | <1% | 7,694 | $115K | |
| 95957 | <1% | 515 | $112K | |
| 43235 | <1% | 270 | $112K | |
| 95812 | <1% | 592 | $111K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,661 | $111K |
| 87902 | <1% | 627 | $111K | |
| 86140 | <1% | 10,701 | $111K | |
| 76536 | <1% | 1,810 | $109K | |
| 73080 | <1% | 3,037 | $108K | |
| 83735 | <1% | 11,934 | $108K | |
| 73030 | <1% | 4,252 | $107K | |
| 72100 | <1% | 3,610 | $105K | |
| 85610 | <1% | 13,238 | $103K | |
| 72141 | <1% | 481 | $101K | |
| 83615 | <1% | 7,389 | $100K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 387 | $99K |
| 58571 | <1% | 69 | $98K | |
| 94150 | <1% | 1,871 | $97K | |
| 83605 | <1% | 6,513 | $97K | |
| 86850 | <1% | 7,678 | $95K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,434 | $95K |
| 86780 | <1% | 5,694 | $91K | |
| 82565 | <1% | 4,187 | $91K | |
| 59025 | Fetal non-stress test | <1% | 2,156 | $90K |
| 82977 | <1% | 4,788 | $89K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,912 | $87K |
| C1769 | Guide wire | <1% | 3,180 | $82K |
| 94664 | <1% | 4,064 | $81K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 953 | $81K |
| 76642 | <1% | 1,621 | $80K | |
| 84550 | <1% | 5,617 | $79K | |
| 73590 | <1% | 2,406 | $78K | |
| 84702 | <1% | 3,930 | $77K | |
| 73090 | <1% | 2,039 | $76K | |
| 88304 | <1% | 1,017 | $76K | |
| 70486 | <1% | 829 | $75K | |
| 93970 | <1% | 769 | $74K | |
| 82607 | <1% | 5,911 | $74K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,041 | $74K |
| 88342 | <1% | 1,669 | $73K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 523 | $73K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 708 | $73K |
| 86900 | <1% | 7,386 | $73K | |
| 87077 | <1% | 5,994 | $73K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,476 | $73K |
| 73502 | <1% | 2,874 | $72K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,171 | $72K |
| 76775 | <1% | 1,800 | $70K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,194 | $70K |
| 97165 | <1% | 2,035 | $69K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,111 | $69K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,583 | $69K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,497 | $68K |
| 85651 | <1% | 7,549 | $68K | |
| 83970 | <1% | 2,309 | $68K | |
| 82728 | <1% | 5,833 | $68K | |
| 86901 | <1% | 7,680 | $67K | |
| 70496 | <1% | 253 | $67K | |
| 87205 | <1% | 4,589 | $66K | |
| 93701 | <1% | 2,613 | $65K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,747 | $65K |
| C1729 | Catheter, drainage | <1% | 2,418 | $65K |
| 94726 | <1% | 2,438 | $64K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 340 | $64K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 590 | $62K |
| 0042T | <1% | 117 | $62K | |
| 83516 | <1% | 3,412 | $59K | |
| 87400 | <1% | 1,265 | $58K | |
| 87536 | <1% | 724 | $57K | |
| 76801 | <1% | 581 | $57K | |
| 96417 | <1% | 1,455 | $57K | |
| 85730 | <1% | 5,327 | $56K | |
| 87075 | <1% | 2,232 | $56K | |
| 82248 | <1% | 4,465 | $56K | |
| 72170 | <1% | 2,194 | $56K | |
| 87088 | <1% | 2,719 | $56K | |
| 70491 | <1% | 194 | $55K | |
| 72050 | <1% | 1,471 | $54K | |
| 82570 | <1% | 7,854 | $54K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,414 | $54K |
| 83721 | <1% | 4,935 | $54K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,218 | $53K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 475 | $53K |
| 84156 | <1% | 4,444 | $53K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,972 | $52K |
| 72072 | <1% | 1,362 | $52K | |
| 77066 | Tomosynthesis, mammo | <1% | 767 | $52K |
| 77386 | <1% | 422 | $52K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,667 | $51K |
| 83550 | <1% | 6,015 | $51K | |
| 84100 | <1% | 5,092 | $51K | |
| 87653 | <1% | 1,450 | $51K | |
| 74022 | <1% | 879 | $51K | |
| 70498 | <1% | 182 | $51K | |
| 87340 | <1% | 3,496 | $50K | |
| V2632 | Posterior chamber intraocular lens | <1% | 617 | $49K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 314 | $49K |
| 82746 | <1% | 3,895 | $48K | |
| 83540 | <1% | 6,229 | $48K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,055 | $47K |
| 88341 | <1% | 639 | $46K | |
| 10060 | <1% | 436 | $45K | |
| 80050 | General health panel | <1% | 1,515 | $45K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,154 | $45K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,978 | $44K |
| 72114 | <1% | 881 | $43K | |
| 86360 | <1% | 455 | $42K | |
| 95700 | <1% | 504 | $41K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,323 | $40K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,413 | $40K |
| 82043 | <1% | 5,818 | $40K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 823 | $39K |
| 73552 | <1% | 1,470 | $39K | |
| 94729 | <1% | 1,828 | $39K | |
| 86762 | <1% | 2,292 | $38K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 2,777 | $37K |
| 77412 | <1% | 275 | $37K | |
| 77065 | Tomosynthesis, mammo | <1% | 826 | $36K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 5,662 | $36K |
| 76870 | <1% | 346 | $36K | |
| 90686 | <1% | 2,920 | $36K | |
| 73560 | <1% | 1,362 | $35K | |
| 82784 | <1% | 1,218 | $35K | |
| 90715 | <1% | 1,594 | $35K | |
| 84145 | <1% | 2,001 | $34K | |
| 72082 | <1% | 693 | $34K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 894 | $33K |
| 87506 | <1% | 245 | $33K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 34 | $32K |
| 86803 | <1% | 2,246 | $32K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 86 | $32K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,375 | $32K |
| 76818 | <1% | 300 | $31K | |
| 64494 | <1% | 437 | $31K | |
| 94010 | <1% | 1,207 | $31K | |
| 82150 | <1% | 2,393 | $31K | |
| 82550 | <1% | 2,169 | $31K | |
| 76882 | <1% | 550 | $31K | |
| 64495 | <1% | 359 | $29K | |
| 95913 | <1% | 271 | $28K | |
| 86706 | <1% | 1,685 | $28K | |
| 95951 | <1% | 108 | $28K | |
| 84481 | <1% | 977 | $27K | |
| 94060 | <1% | 904 | $27K | |
| 73562 | <1% | 1,335 | $27K | |
| 86038 | <1% | 1,621 | $27K | |
| 73060 | <1% | 649 | $26K | |
| 73140 | <1% | 707 | $26K | |
| 93976 | <1% | 400 | $25K | |
| 72110 | <1% | 513 | $25K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 227 | $25K |
| 82140 | <1% | 1,584 | $23K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,472 | $22K |
| 82105 | <1% | 903 | $22K | |
| 64642 | <1% | 114 | $21K | |
| 97597 | <1% | 1,140 | $20K | |
| 82378 | <1% | 964 | $20K | |
| 94762 | <1% | 517 | $20K | |
| 93880 | <1% | 302 | $20K | |
| 84146 | <1% | 705 | $19K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 498 | $19K |
| 62323 | <1% | 15 | $19K | |
| 95953 | <1% | 36 | $19K | |
| 64635 | <1% | 222 | $19K | |
| 85379 | <1% | 1,402 | $19K | |
| 87081 | <1% | 812 | $18K | |
| 86235 | <1% | 371 | $18K | |
| 83655 | <1% | 885 | $18K | |
| 84403 | <1% | 788 | $18K | |
| 88112 | <1% | 676 | $18K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,072 | $17K |
| 82950 | <1% | 1,422 | $17K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,046 | $17K |
| 84153 | <1% | 1,043 | $17K | |
| 86255 | <1% | 985 | $17K | |
| 83883 | <1% | 484 | $17K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 12 | $16K |
| 73700 | <1% | 177 | $16K | |
| 86480 | <1% | 292 | $16K | |
| 86704 | <1% | 863 | $16K | |
| 82330 | <1% | 1,099 | $15K | |
| 87808 | <1% | 628 | $15K | |
| 86707 | <1% | 688 | $15K | |
| 95874 | <1% | 577 | $15K | |
| 95708 | <1% | 87 | $15K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 41 | $15K |
| 72040 | <1% | 512 | $15K | |
| 86200 | <1% | 504 | $15K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 876 | $15K |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | <1% | 189 | $15K |
| 87350 | <1% | 687 | $15K | |
| 73521 | <1% | 339 | $15K | |
| 80164 | <1% | 729 | $15K | |
| 97602 | <1% | 572 | $14K | |
| 83001 | <1% | 669 | $14K | |
| 70360 | <1% | 358 | $14K | |
| 72052 | <1% | 267 | $14K | |
| 86708 | <1% | 880 | $14K | |
| 95813 | <1% | 54 | $14K | |
| 86430 | <1% | 758 | $14K | |
| 83010 | <1% | 310 | $14K | |
| 19083 | <1% | 44 | $13K | |
| 80076 | <1% | 1,190 | $13K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 520 | $13K |
| 86705 | <1% | 664 | $13K | |
| 93923 | <1% | 185 | $13K | |
| 95912 | <1% | 120 | $13K | |
| 20550 | <1% | 230 | $13K | |
| 93922 | <1% | 362 | $12K | |
| 86376 | <1% | 754 | $12K | |
| 96411 | <1% | 253 | $12K | |
| 97116 | <1% | 718 | $12K | |
| 82533 | <1% | 577 | $12K | |
| 74019 | <1% | 360 | $12K | |
| 76813 | <1% | 196 | $12K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 828 | $11K |
| 82247 | <1% | 475 | $11K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,026 | $11K |
| 77080 | <1% | 183 | $11K | |
| 95819 | <1% | 57 | $11K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 553 | $11K |
| 85045 | <1% | 1,499 | $11K | |
| 84460 | <1% | 454 | $11K | |
| 88185 | <1% | 56 | $11K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 237 | $10K |
| 97162 | <1% | 302 | $10K | |
| 81596 | <1% | 169 | $10K | |
| 86800 | <1% | 476 | $10K | |
| 95816 | <1% | 72 | $9K | |
| 84165 | <1% | 489 | $9K | |
| 88300 | <1% | 311 | $9K | |
| 77334 | <1% | 92 | $9K | |
| 64636 | <1% | 171 | $9K | |
| 90732 | <1% | 210 | $9K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 465 | $8K |
| 97166 | <1% | 316 | $8K | |
| 72158 | <1% | 42 | $8K | |
| 91200 | <1% | 191 | $8K | |
| 82172 | <1% | 235 | $8K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 43 | $8K |
| 20552 | <1% | 58 | $7K | |
| 51729 | <1% | 15 | $7K | |
| 86258 | <1% | 1,102 | $7K | |
| 64633 | <1% | 17 | $7K | |
| 51797 | <1% | 73 | $7K | |
| 88313 | <1% | 68 | $7K | |
| 95714 | <1% | 69 | $7K | |
| 84402 | <1% | 278 | $7K | |
| 12001 | <1% | 136 | $7K | |
| 86147 | <1% | 42 | $7K | |
| 49083 | <1% | 89 | $6K | |
| 64634 | <1% | 19 | $6K | |
| 80320 | <1% | 186 | $6K | |
| 95911 | <1% | 114 | $6K | |
| 76937 | <1% | 80 | $6K | |
| 84520 | <1% | 74 | $6K | |
| P9041 | Infusion, albumin (human), 5%, 50 ml | <1% | 271 | $6K |
| 58300 | <1% | 86 | $6K | |
| 82785 | <1% | 384 | $6K | |
| 64643 | <1% | 61 | $6K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 78 | $6K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,405 | $6K |
| 72131 | <1% | 45 | $5K | |
| 73000 | <1% | 169 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 163 | $5K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 315 | $5K |
| 83002 | <1% | 213 | $5K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 297 | $5K |
| 96368 | <1% | 193 | $5K | |
| 77002 | <1% | 39 | $5K | |
| 85384 | <1% | 210 | $5K | |
| 82009 | <1% | 480 | $5K | |
| 88173 | <1% | 65 | $5K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 12 | $4K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 258 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 256 | $4K |
| 80055 | <1% | 118 | $4K | |
| 91322 | <1% | 177 | $4K | |
| 86160 | <1% | 237 | $4K | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 36 | $4K |
| 83090 | <1% | 17 | $4K | |
| 74220 | <1% | 81 | $4K | |
| 86231 | <1% | 541 | $4K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 18 | $4K |
| 95910 | <1% | 43 | $4K | |
| 81513 | <1% | 56 | $4K | |
| 11721 | <1% | 781 | $4K | |
| 74241 | <1% | 21 | $4K | |
| 88172 | <1% | 50 | $4K | |
| 84425 | <1% | 184 | $4K | |
| 93225 | <1% | 89 | $3K | |
| 94618 | <1% | 190 | $3K | |
| 82575 | <1% | 145 | $3K | |
| 84112 | <1% | 46 | $3K | |
| 51784 | <1% | 88 | $3K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 322 | $3K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 146 | $3K |
| 86665 | <1% | 126 | $3K | |
| 72156 | <1% | 12 | $3K | |
| 76825 | <1% | 14 | $3K | |
| 77062 | <1% | 99 | $3K | |
| 87015 | <1% | 66 | $3K | |
| 80081 | <1% | 43 | $3K | |
| 87102 | <1% | 98 | $3K | |
| 87116 | <1% | 66 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 367 | $3K |
| 74270 | <1% | 28 | $3K | |
| 36600 | <1% | 284 | $3K | |
| 90670 | <1% | 20 | $3K | |
| 83519 | <1% | 68 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 28 | $3K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 94 | $3K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $2K |
| 51741 | <1% | 69 | $2K | |
| 73221 | <1% | 19 | $2K | |
| 84436 | <1% | 184 | $2K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 163 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 285 | $2K |
| 77290 | <1% | 19 | $2K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 45 | $2K |
| 88312 | <1% | 34 | $2K | |
| 86664 | <1% | 97 | $2K | |
| 89050 | <1% | 116 | $2K | |
| 77300 | <1% | 34 | $2K | |
| 64490 | <1% | 24 | $2K | |
| L3808 | Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment | <1% | 15 | $2K |
| 84134 | <1% | 144 | $2K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 137 | $2K |
| 77061 | <1% | 246 | $2K | |
| 80202 | <1% | 47 | $2K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 70 | $2K |
| 85460 | <1% | 47 | $2K | |
| 90677 | <1% | 32 | $2K | |
| 86663 | <1% | 70 | $2K | |
| 80143 | <1% | 107 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,327 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 79 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,103 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 220 | $2K |
| 87521 | Neg quan hep c or qual rna | <1% | 54 | $2K |
| 84681 | <1% | 30 | $2K | |
| 85018 | <1% | 564 | $2K | |
| 86778 | <1% | 58 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 696 | $1K |
| 80177 | <1% | 40 | $1K | |
| 85461 | <1% | 140 | $1K | |
| 88184 | <1% | 56 | $1K | |
| 70250 | <1% | 49 | $1K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 15 | $1K |
| 85240 | <1% | 55 | $1K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 73 | $1K |
| 87481 | <1% | 78 | $1K | |
| 83520 | <1% | 31 | $1K | |
| 94760 | <1% | 458 | $1K | |
| 85014 | <1% | 489 | $1K | |
| 76376 | <1% | 35 | $1K | |
| 86920 | <1% | 52 | $1K | |
| 86336 | <1% | 46 | $1K | |
| 86777 | <1% | 62 | $1K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 111 | $1K |
| 80178 | <1% | 94 | $1K | |
| 86304 | <1% | 61 | $1K | |
| 99490 | Ccm add 20min | <1% | 277 | $1K |
| 80329 | <1% | 27 | $1K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 78 | $1K |
| 72220 | <1% | 12 | $979.36 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 989 | $976.82 |
| 86225 | <1% | 40 | $966.61 | |
| 93307 | <1% | 15 | $965.17 | |
| 76641 | <1% | 16 | $960.17 | |
| 86618 | <1% | 112 | $940.40 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 168 | $939.87 |
| 16020 | <1% | 13 | $906.28 | |
| 97804 | <1% | 15 | $873.59 | |
| 87807 | <1% | 22 | $822.18 | |
| 82670 | <1% | 39 | $821.78 | |
| 83992 | <1% | 47 | $815.16 | |
| C1758 | Catheter, ureteral | <1% | 101 | $810.96 |
| 90662 | <1% | 254 | $805.71 | |
| 82103 | <1% | 83 | $804.93 | |
| 85705 | <1% | 26 | $798.22 | |
| 73600 | <1% | 43 | $793.52 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 139 | $775.39 |
| 93325 | <1% | 13 | $761.46 | |
| 87529 | <1% | 24 | $759.72 | |
| 84450 | <1% | 55 | $737.38 | |
| 86923 | <1% | 55 | $734.02 | |
| 71101 | <1% | 44 | $733.59 | |
| 84163 | <1% | 32 | $692.40 | |
| 12002 | <1% | 13 | $683.15 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 68 | $680.58 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 325 | $654.08 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 383 | $632.90 |
| 64492 | <1% | 21 | $625.82 | |
| 64491 | <1% | 21 | $625.80 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 245 | $614.78 |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 129 | $613.01 |
| 80179 | <1% | 38 | $602.07 | |
| 80375 | <1% | 41 | $593.97 | |
| 86308 | <1% | 53 | $576.20 | |
| 86141 | <1% | 25 | $574.79 | |
| 84432 | <1% | 12 | $566.46 | |
| 73100 | <1% | 30 | $559.92 | |
| 90656 | <1% | 180 | $554.94 | |
| 73620 | <1% | 28 | $541.19 | |
| 20526 | <1% | 27 | $515.34 | |
| 82951 | <1% | 29 | $511.94 | |
| 82652 | <1% | 16 | $507.94 | |
| 97164 | <1% | 13 | $498.88 | |
| 51798 | <1% | 127 | $486.32 | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 28 | $472.69 |
| 36430 | <1% | 16 | $463.50 | |
| 99442 | <1% | 14 | $460.20 | |
| 87209 | <1% | 34 | $457.98 | |
| 11981 | <1% | 14 | $438.69 | |
| 90653 | <1% | 64 | $425.73 | |
| 88302 | <1% | 28 | $405.03 | |
| 90480 | <1% | 177 | $391.25 | |
| 82952 | <1% | 16 | $385.96 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 321 | $366.01 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 224 | $365.60 |
| 86300 | <1% | 15 | $362.08 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 226 | $357.01 |
| 84155 | <1% | 130 | $339.80 | |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 76 | $339.79 |
| 87329 | <1% | 47 | $338.88 | |
| 00731 | <1% | 29 | $337.24 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 45 | $325.30 |
| 82024 | <1% | 13 | $323.08 | |
| 84300 | <1% | 97 | $320.42 | |
| 73120 | <1% | 19 | $300.60 | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 31 | $298.72 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 43 | $289.52 |
| 12011 | <1% | 17 | $287.21 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 177 | $284.25 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $279.22 |
| 98960 | <1% | 20 | $272.05 | |
| 71100 | <1% | 15 | $271.13 | |
| 94660 | <1% | 15 | $263.79 | |
| 87428 | <1% | 148 | $259.01 | |
| 86003 | <1% | 12 | $256.25 | |
| 85246 | <1% | 13 | $235.61 | |
| 77072 | <1% | 13 | $219.32 | |
| 83993 | <1% | 12 | $203.17 | |
| 82040 | <1% | 12 | $196.28 | |
| 94667 | <1% | 15 | $174.90 | |
| 84154 | <1% | 12 | $173.44 | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 51 | $156.07 |
| 87493 | <1% | 14 | $154.94 | |
| 86592 | <1% | 38 | $140.65 | |
| 86015 | <1% | 16 | $136.14 | |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | <1% | 12 | $135.68 |
| 0134A | <1% | 53 | $115.68 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 12 | $113.69 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 86 | $111.13 |
| 81002 | <1% | 78 | $100.84 | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 27 | $100.33 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 56 | $84.28 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 359 | $74.72 |
| 93296 | <1% | 43 | $72.60 | |
| 11720 | <1% | 15 | $72.40 | |
| 0064A | <1% | 18 | $66.74 | |
| 0124A | <1% | 38 | $53.95 | |
| 82947 | <1% | 13 | $52.44 | |
| 82272 | <1% | 15 | $45.53 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 53 | $41.13 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 32 | $37.71 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 66 | $36.83 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 47 | $29.15 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 34 | $22.77 |
| 99439 | <1% | 14 | $22.66 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 10,455 | $19.60 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 24 | $19.49 |
| 81015 | <1% | 15 | $11.17 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 28 | $6.92 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 17 | $6.53 |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | <1% | 23 | $6.22 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 15 | $5.76 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 21 | $0.39 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 45 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 45 | $0.00 |
| 3008F | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARTIN, TIM (VP & COO)
| Provider | Location | Paid |
|---|---|---|
| Cabell Huntington Hospital INC | Huntington, WV | $9.27M |
| Cabell Huntington Hospital, INC | Huntington, WV | $295K |
| TWMH LLC | Abilene, TX | $1K |
| DR Tim Martin MD PLLC | Abilene, TX | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.